New advancement of AML

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDepartment of Pharmacology and Pharmacotherapyhu_HU
dc.contributor.authorTanaka, Kentaro
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-08-29T09:49:49Z
dc.date.available2022-08-29T09:49:49Z
dc.date.created2022-03-08
dc.description.abstractAML is a rare malignancies of hematopoietic stem cells. AML is treated by intensive chemotherapy (combination of Ara-C and daunorubicin is the most common choice) as a pre-transplantation. After reaching morphological complete remission, HSCT is done if the patients meet the indication of it. As the post-transplantation therapy, prophylactic corticosteroid, supportive therapy and isolation are important to reduce risks of infection due to weak immunity of patient. New medications such as FLT3 inhibitors, GO, IDH inhibitors, glasdegib or Vyxeos are selected when traditional therapy is ineffective or relapsing after complete remission. Such recent medications increase disease free period and improves prognosis of AML relating to a certain gene mutation, for instance FLT3, IDH 1 and 2. However, they are still far from perfect because of the formation resistance against these medications and many varieties of mutations are associated with AML. Furthermore, side effects of drugs are still serious. Myelosuppression, TLS and febrile neutropenia are life-threatening conditions even prevention and management methods are established. These problems must be overcame in the future with evolution of technology.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent37hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/336886
dc.language.isoenhu_HU
dc.subjectAMLhu_HU
dc.subjectFLT3 inhibitorhu_HU
dc.subjectGemtuzumab ozogamicinhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleNew advancement of AMLhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)